No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
Identifieur interne : 001A36 ( Main/Corpus ); précédent : 001A35; suivant : 001A37No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
Auteurs : J M Molina ; C. Delaugerre ; J. Le Goff ; B. Mela-Lima ; D. Ponscarme ; L. Goldwirt ; N. De CastroSource :
- Medecine et maladies infectieuses [ 1769-6690 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), Betacoronavirus (isolation & purification), COVID-19 (MeSH), Coronavirus Infections (therapy), Drug Therapy, Combination (standards), Female (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (therapy), SARS-CoV-2 (MeSH), Treatment Outcome (MeSH), Young Adult (MeSH).
- MESH :
- chemical , therapeutic use : Antiviral Agents, Azithromycin, Hydroxychloroquine.
- isolation & purification : Betacoronavirus.
- standards : Drug Therapy, Combination.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Adult, Aged, COVID-19, Female, Humans, Male, Middle Aged, Pandemics, SARS-CoV-2, Treatment Outcome, Young Adult.
DOI: 10.1016/j.medmal.2020.03.006
PubMed: 32240719
PubMed Central: PMC7195369
Links to Exploration step
pubmed:32240719Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.</title>
<author><name sortKey="Molina, J M" sort="Molina, J M" uniqKey="Molina J" first="J M" last="Molina">J M Molina</name>
<affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France; U944 INSERM, université de Paris, 75000 Paris, France. Electronic address: jean-michel.molina@aphp.fr.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Delaugerre, C" sort="Delaugerre, C" uniqKey="Delaugerre C" first="C" last="Delaugerre">C. Delaugerre</name>
<affiliation><nlm:affiliation>Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Le Goff, J" sort="Le Goff, J" uniqKey="Le Goff J" first="J" last="Le Goff">J. Le Goff</name>
<affiliation><nlm:affiliation>Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mela Lima, B" sort="Mela Lima, B" uniqKey="Mela Lima B" first="B" last="Mela-Lima">B. Mela-Lima</name>
<affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ponscarme, D" sort="Ponscarme, D" uniqKey="Ponscarme D" first="D" last="Ponscarme">D. Ponscarme</name>
<affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Goldwirt, L" sort="Goldwirt, L" uniqKey="Goldwirt L" first="L" last="Goldwirt">L. Goldwirt</name>
<affiliation><nlm:affiliation>Pharmacology Department, AP-HP, Saint-Louis Hospital, 75010 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Castro, N" sort="De Castro, N" uniqKey="De Castro N" first="N" last="De Castro">N. De Castro</name>
<affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32240719</idno>
<idno type="pmid">32240719</idno>
<idno type="doi">10.1016/j.medmal.2020.03.006</idno>
<idno type="pmc">PMC7195369</idno>
<idno type="wicri:Area/Main/Corpus">001A36</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A36</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.</title>
<author><name sortKey="Molina, J M" sort="Molina, J M" uniqKey="Molina J" first="J M" last="Molina">J M Molina</name>
<affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France; U944 INSERM, université de Paris, 75000 Paris, France. Electronic address: jean-michel.molina@aphp.fr.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Delaugerre, C" sort="Delaugerre, C" uniqKey="Delaugerre C" first="C" last="Delaugerre">C. Delaugerre</name>
<affiliation><nlm:affiliation>Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Le Goff, J" sort="Le Goff, J" uniqKey="Le Goff J" first="J" last="Le Goff">J. Le Goff</name>
<affiliation><nlm:affiliation>Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mela Lima, B" sort="Mela Lima, B" uniqKey="Mela Lima B" first="B" last="Mela-Lima">B. Mela-Lima</name>
<affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ponscarme, D" sort="Ponscarme, D" uniqKey="Ponscarme D" first="D" last="Ponscarme">D. Ponscarme</name>
<affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Goldwirt, L" sort="Goldwirt, L" uniqKey="Goldwirt L" first="L" last="Goldwirt">L. Goldwirt</name>
<affiliation><nlm:affiliation>Pharmacology Department, AP-HP, Saint-Louis Hospital, 75010 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Castro, N" sort="De Castro, N" uniqKey="De Castro N" first="N" last="De Castro">N. De Castro</name>
<affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Medecine et maladies infectieuses</title>
<idno type="eISSN">1769-6690</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Azithromycin (therapeutic use)</term>
<term>Betacoronavirus (isolation & purification)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Drug Therapy, Combination (standards)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Drug Therapy, Combination</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>COVID-19</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32240719</PMID>
<DateCompleted><Year>2020</Year>
<Month>05</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1769-6690</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>50</Volume>
<Issue>4</Issue>
<PubDate><Year>2020</Year>
<Month>06</Month>
</PubDate>
</JournalIssue>
<Title>Medecine et maladies infectieuses</Title>
<ISOAbbreviation>Med Mal Infect</ISOAbbreviation>
</Journal>
<ArticleTitle>No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.</ArticleTitle>
<Pagination><MedlinePgn>384</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0399-077X(20)30085-8</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medmal.2020.03.006</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Molina</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France; U944 INSERM, université de Paris, 75000 Paris, France. Electronic address: jean-michel.molina@aphp.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Delaugerre</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Le Goff</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mela-Lima</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ponscarme</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Goldwirt</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Pharmacology Department, AP-HP, Saint-Louis Hospital, 75010 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>de Castro</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>03</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Med Mal Infect</MedlineTA>
<NlmUniqueID>0311416</NlmUniqueID>
<ISSNLinking>0399-077X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>03</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>5</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId>
<ArticleId IdType="pii">S0399-077X(20)30085-8</ArticleId>
<ArticleId IdType="doi">10.1016/j.medmal.2020.03.006</ArticleId>
<ArticleId IdType="pmc">PMC7195369</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2012 Jul 25;308(4):353-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22820788</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Negl Trop Dis. 2010 Aug 10;4(8):e785</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20706626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2011 Sep;11(9):677-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21550310</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2018 May 17;10(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29772762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28596841</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001A36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32240719 |texte= No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32240719" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |